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Abstract
Background: There are minimal reports of seasonal variations in chronic heart failure (CHF)-related morbidity and mortality beyond the
northern hemisphere.
Aims and methods: We examined potential seasonal variations with respect to morbidity and all-cause mortality over more than a decade in a
cohort of 2961 patients with CHF from a tertiary referral hospital in South Australia subject to mild winters and hot summers.
Results: Seasonal variation across all event-types was observed. CHF-related morbidity peaked in winter (July) and was lowest in summer
(February): 70 (95%CI: 65 to 76) vs. 33 (95%CI: 30 to 37) admissions/1000 at risk (pb0.005). All-cause admissions (113 (95%CI: 107 to 120)
vs. 73 (95% CI 68 to 79) admissions/1000 at risk, pb0.001) and concurrent respiratory disease (21% vs. 12%, pb0.001) were consistently
higher in winter. 2010 patients died, mortality was highest in August relative to February: 23 (95%CI: 20 to 27) vs. 12 (95%CI: 10 to 15) deaths
per 1000 at risk, pb0.001. Those aged 75 years or older were most at risk of seasonal variations in morbidity and mortality.
Conclusion: Seasonal variations in CHF-related morbidity and mortality occur in the hot climate of South Australia, suggesting that relative
(rather than absolute) changes in temperature drive this global phenomenon.
Crown Copyright © 2008 Published by Elsevier B.V. on behalf of European Society of Cardiology. All rights reserved.
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1. Introduction
The phenomenon of seasonal variations in chronic heart
failure (CHF)-related morbidity and mortality, characterised
by excess events in winter months is well described in the
northern hemisphere [1–4]. Conversely, there are few studies
focussing on this phenomenon in the southern hemisphere
[5]. As such, the impact of potentially important differences
in external triggers for fatal and non-fatal acute exacerba-
tions of CHF in various populations and high risk subsets of
the CHF population has not been fully explored.
Observed increases in morbidity and mortality in colder
monthsmay be explained largely by physiologicalmechanisms.
A lower body temperature on admission has been associated
with adverse prognosis in patients with advanced CHF [6].
Whether this association is due to vasoconstriction, an increase
in heart failure and blood pressure [7] or a marker of advanced
CHF reflecting thermal dysregulation and neurohormonal acti-
vation has not yet been determined. Other seasonal variations,
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such as the incidence of respiratory infections may further
undermine the fragile state of health of these patients.
In Australia's warm climate, CHF still exerts a substantial
burden on the population [8] and health care system [9] with
strong anecdotal evidence ofwinter peaks in hospital admissions
due to concurrent respiratory disease and acuteHF.Whether this
is an accurate picture of the situation in the southern hemisphere,
and in particular in southern Australia has not been determined.
The impact of high temperatures on CHF morbidity and mor-
tality has to our knowledge not been examined.
The aim of this study was to examine the pattern of
morbidity and mortality in patients with CHF living in the
Australian state of South Australia (population 1.5 million)
over an 11 year period according to the time of the year and
weather patterns. A null hypothesis was tested — that there
is no difference in the rate of events in patients with CHF
living in South Australia according to the time of year.
2. Methods
2.1. Setting
The Australian state of South Australia is described as
having a Mediterranean-style climate, with hot dry summers
(2006 mean maximum temperature was 23.1 °C) and cool
winters (2006meanminimum temperature was 12.1 °C— see
Table 1) [10,11]. Some parts of the region experience quite
dramatic climates with temperatures as high as 47.4 °C in
summer! [10,11] Most of the 1.5 million resident South
Australians live in urban areas located in coastal regions. The
estimated prevalence of CHF within the total South Australian
population (1.9%) [12] is consistent with reports from
developed countries.
2.2. Participants, diagnosis and data sources
We undertook a retrospective analysis of longitudinal
routinely collected clinical data for a cohort of 2961 patients
with a diagnosis of CHF admitted to the largest tertiary referral
hospital in the city of Adelaide, South Australia. CHF diag-
nosis was confirmed by a combination of documented evi-
dence of clinical symptoms equivalent to those included in
Framingham criteria [13], echocardiographic data and other
cardiac investigations such as coronary angiography (verified
by study authors). Patients admitted with a principal diagnosis
of CHF between 1 July 1994 and 30 June 2004 to the General
Medical Ward or Cardiology unit and discharged alive were
recruited to the cohort. Follow-up was performed from index
Table 1
South Australian climate data [10,11]
Season and month of
the year
Mean min temperature
1997–2007
Mean max temperature
1997–2007
Average min–max
1997–2007
1997–2007 Mean relative humidity
1997–2007
°C °C °C mm %
Autumn March 15.1 26.2 7.2–41.9 25.5 42
April 12.3 22.5 4.3–36.9 39.4 47
May 10.2 19.0 1.5–29.2 59.8 71
Winter June 8.1 16.1 −0.4–25.4 82.2 62
July 7.4 15.3 0.4–23.1 74.9 61
August 8.2 16.7 1.6–30.4 66.6 55
Spring September 9.6 18.9 2.6–34.3 61.7 52
October 11.4 21.7 4.7–39.0 46.3 45
November 13.8 24.8 5.7–42.0 32.1 41
Summer December 15.5 26.9 8.0–42.5 27.6 40
January 17.0 28.9 9.2–44.2 20.6 37
February 17.0 29.3 9.5–44.3 13.2 37
Average for South Australia 12.1 22.2 −0.4–44.3 551.7⁎ 48
⁎ Total annual rainfall.
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admission to either death or study census (30 June 2005).
These data include all index and subsequent admissions.
Data included is from that collected as part of a clinical
cohort registry. Admissions data and patient demographics are
from the Royal Adelaide Hospital patient master index. Death
datawas obtained fromofficial death certificate records from the
National Death Index. Comorbidities were derived from the
International Classification of Diseases (ICD) coding, and the
prescribed medications from pharmacy dispensing data. A
sample of records was used to validate comorbidity and pre-
scribedmedication data against case notes to ensure its accuracy.
Biochemistry data was extracted using linked records from the
Institute of Medical and Veterinary Sciences, which is the sole
pathology provider to the Royal Adelaide Hospital. Echocar-
diography datawas derived using linked data from the hospital's
echocardiogram database, although the availability of this data
was limited. Standard bi-plane left ventricular ejection fraction
was calculated utilizing Simpson's Method of Discs, following
manual tracing of endocardial borders on apical 4-chamber and
long axis views.
The Royal Adelaide Hospital is a large tertiary referral
centre for all regions of South Australia and there are only a
small number of other public hospitals in the state to which
these patients would have been readmitted. A review of a
sample of readmission data has revealed that few of the
readmissions relating to these patients occurred to other
South Australian public hospitals.
2.3. Study definitions
For the purpose of this study, CHF was defined according
to recently published Australian guidelines [14] as outlined
above. The primary outcomes of interest are defined below.
Length of stay was calculated to include the number of days
the patient occupied a bed inclusive of admission and dis-
charge dates.
CHF-related hospitalisations were identified by a dis-
charge diagnosis coding of CHF in either the first or second
diagnostic position for an unplanned admission to hospital. A
CHF-related discharge diagnosis code was considered to be
one of the following: ICD-9 402.91, 425, 428, 518.4; ICD-10
I11.0, I13.0, I13.2, I25.5, I42, I43, I50, J81. Consistent with
previous reports, [1,2] all aetiologic forms of CHF and epi-
sodes of pulmonary oedemawere included. Previous case note
review corresponding to over 1000 patients in this cohort has
demonstrated that these codes have greater than 99% speci-
ficity for the presence of the Framingham criteria for CHF
during the admission [15].
The contribution of respiratory-related morbidity to CHF-
related hospitalisations was examined and compared for
months with the highest and lowest event rate. We identified
unplanned hospitalisations where a CHF-related code and a
respiratory code (ICD-9 460–519; ICD-10 J00–J99) were
present. Length of stay was also examined.
All-cause hospitalisations included all unplanned admis-
sions to hospital for any cause.
All-cause mortality included deaths from any cause. Data
was obtained from official death certificate records linked to
patient hospital record numbers from the National Death
Index. The underlying mortality rate in the population from
which this cohort is derived was considered. South Australian
mortality and population data was obtained from the South
Australian Department of Health.
2.4. Ethics
All patient data was de-identified prior to analysis. Ethics
approval to collect and analyse these data was granted by the
relevant institutional ethics committees. This study conformed
to the principles outlined in the Declaration of Helsinki.
Table 2
Patient demographics at recruitment a
Patient characteristics on recruitment Total
n=2961
Male 1490 (50%)
Age (mean±SD) 75±13 years
Country of birth not Australia 1395 (47%)
Discharged to own home 2310 (78%)
Left ventricular ejection fraction (%) (mean±SD) 33.5±13.6%
Proportion with LVEF b40%b 67 (68%)
Functional scale (left ventricular function) b
Preserved 222 (30%)
Mild 112 (15%)
Mild–moderate 93 (12%)
Moderate 102 (13%)
Moderate–severe 125 (17%)
Severe 99 (13%)
Biochemistry and haematology (mean±SD)
Na+ mmol/L 138.0±4.1
K+ mmol/L 4.2±0.7
Creatinine mmol/L 135.0±74.0
Hb g/dL 12.4±2.0
Male Hb 12.8±2.1
Female Hb 12.0±1.9
Comorbidities
Ischaemic heart disease 1415 (49%)
Hypertension 1122 (38%)
Diabetes mellitus 800 (27%)
Atrial fibrillation/flutter 954 (32%)
Chronic obstructive airways disease 500 (17%)
Chronic renal failure 355 (12%)
Peripheral arterial disease 252 (9%)
Cerebrovascular disease 154 (5%)
Asthma 153 (5%)
Dementia 122 (4%)
Anaemia c
Male 344 (52%)
Female 323 (49%)
CHF medications
ACE inhibitor 1681 (67%)
Β-blocker 532 (67%)
Renin–angiotensin system agent d 1781 (71%)
a Not all clinical data available for all patients, % are calculated according
to the number of patients for whom data was available.
b Data not available for same number of patients.
c Defined according to clinical coding (ICD code).
d Excludes aldosterone receptor antagonists.
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2.5. Statistical analysis
As data analysis comprises an eleven year study period,
during which time there were fatal events, the number of
patients at risk of an event (hospitalisation or death) for each
month of the year and year of follow-up was calculated
according to index admission dates and dates of death until the
census date (30 June 2005) allowing adjustment for study
entry and death.
The total number of events occurring during each month
for the 11 years of the study (inclusive of the index admission)
was calculated and divided by the total number of patients at
risk of the event for that month over the 11 year study period.
These rates are expressed per 1000 patients at risk per month
with 95% confidence intervals. The proportion of events and
the proportion of concomitant respiratory codes for CHF-
related admissions according to the number at risk for the
months with the highest and lowest event rates were then
compared using Fishers exact test with p values b0.05 con-
sidered statistically significant.
Length of stay for CHF-related admissions was analysed
by totalling the number of bed-days accumulated for each
month over the 11 year study period and dividing this by the
total number of CHF-related admissions accumulated for that
month over the same period. These averages for the months
with the longest and shortest lengths of stay were compared
using an independent t-test with p values b0.05 considered
statistically significant. A risk ratio (RR) with 95% confi-
dence intervals comparing the highest and lowest event rates
according to months of the year was calculated by dividing
the total number of events per 1000 at risk accumulated in
months with the highest event rate by the total number of
events per 1000 at risk accumulated inmonths with the lowest
event rate. Average annual and monthly mortality rates were
calculated by averaging the observed monthly mortality rate;
these rates were then compared to South Australian mortality
rates and attributable risk (%) calculated. Data analysis was
performed using SPSS version 15.0.
3. Results
3.1. Clinical and socio-demographic profile
Table 2 provides a summary of the clinical and socio-
demographic profile of the 2961 patients that comprise the
study cohort. Consistent with reports from other developed
countries, patients were elderly and, despite a high comorbid
burden, predominantly lived independently in their own home.
Not all patients were born in Australia, of the 47% born
overseas; the majority (88%) emigrated from Europe in the
first two decades following World War II. The majority of the
cohort resided in metropolitan and urban areas, with a small
number recording their residential address in remote and rural
areas of the State.
3.2. Pattern of chronic heart failure-related unplanned
hospitalisations (1994 to 2005)
Between 1 July 1994 and 30 June 2005 (mean study
follow-up of 36±32 months) a total of 2782 patients (94% of
Table 3
Seasonal variations in the rate of CHF-related hospitalisations and concurrent respiratory disease
Total
events
Average monthly
event rate a
High vs. low months b Observed vs.
expected rate c
Concurrent respiratory
diagnosis (%)
/1000 at risk
(95% CI)
/1000 at risk
(95% CI)
p value p value: low vs.
high month
All (n=2961) 5306 50 July: 70 (65 to 76) b0.001 21 b0.001
(45 to 54) February: 33 (30 to 37) b0.001 12
Female (n=1471) 2652 49 July: 75 (67 to 83) b0.001 20 NS (0.204)
(44 to 56) March: 34 (29 to 40) b0.001 15
Male (n=1490) 2654 50 July: 66 (59 to 74) b0.001 23 NS (0.021)
(44 to 56) February: 32 (27 to 37) b0.001 14
Agedb75 years
(n=1262)
2033 35 July: 47 (41 to 54) 0.002 17 NS (0.105)
(30 to 40) February: 24 (20 to 29) 0.002 10
Aged≥75 years
(n=1699)
3273 67 July: 98 (38 to 51) b0.001 24 0.004
(60 to 75) February: 44 (89 to 108) b0.001 14
Female agedb75 years
(n=469)
765 32 September: 45 (37 to 56) 0.031 19 0.043
(26 to 41) February: 23 (17 to 31) NS (0.066) 7
Female aged≥75 years
(n=1002)
1887 63 July: 100 (89 to 113) b0.001 21 0.031
(54 to 73) March: 41 (34 to 49) b0.001 12
Male agedb75 years
(n=793)
1268 37 August: 47 (39 to 55) NS (0.054) 15 NS (0.535)
(30 to 44) February: 25 (20 to 31) 0.010 12
Male aged≥75 years
(n=697)
1386 74 August: 98 (84 to 114) 0.015 31 0.020
(62 to 88) February: 44 (35 to 55) b0.001 16
a Averagemonthly event rate was calculated by dividing the average accumulated number of patients at risk per month by the average accumulated events per month.
b pb0.001 for all comparisons of low vs. high monthly rates.
c Difference between the calculated average monthly event rate and the observed (for high or low months) monthly event rate.
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total cohort) were discharged from hospital with a diagnosis
of CHF in the first or second diagnostic position. These 2782
patients accumulated 5306 CHF-related admissions to
hospital (mean 1.9±1.7 admissions per patient), of which
48% were recurrent admissions. The underlying expected
rate of admissions was 50 (95%CI 45 to 54) per 1000 patients
at risk per month. The mean length of stay for these admis-
sions was 8.8±8.2 days with a total of 46,669 bed-days
accumulated.
Seasonal variation in CHF-related morbidity was
observed (see Table 3). Specifically, a significantly higher
crude rate of unplanned admissions for CHF according to
the number of patients at risk was observed in July (winter)
with the lowest rate recorded in February (summer): 70
(95% CI: 65 to 76) vs. 33 (95% CI: 30 to 37) admissions per
1000 patients at risk (pb0.005) respectively. Similar trends
were observed across all sub-analyses and event rates were
consistently significantly different between warmer and
cooler months. Fig. 1 depicts the CHF-related unplanned
hospitalisation rate according to sex.
The proportion of concomitantly coded respiratory and
CHF-related admissions was consistently higher in months
with the highest event rate (19%–31% of admissions) re-
lative to months with the lowest event rate (7%–16% of
admissions). Table 3 shows that the majority of event rates in
the winter months were statistically higher than those record-
ed in the warmer summer months.
Overall, length of stay did not vary significantly for those
months with the highest and lowest rates of CHF-related hos-
pitalisations. However, particular sub-groups (males, those aged
≥75 years, males and females aged ≥75 years) experienced
significant variation in length of stay between months. For
males, the longest length of stay was observed in August, with a
mean length of stay of 9.0±1.6 days relative to January, 7.5±
1.5 days (p=0.027). A similar pattern was seen in those aged
≥75 years: August, 9.0±1.8 days vs. January, 7.1±1.4 days
(p=0.011). This trend continued for males aged ≥75 years:
July, 9.2±3.0 days vs. January, 6.3±1.1 days (p=0.007).
Conversely, a different seasonal pattern was seen for females
aged ≥75 years, with November observed to have the long-
est length of stay relative to July, 11.3±6.2 days vs. 6.8±
2.0 days (p=0.040). This group also experienced the greatest
monthly variation in the length of stay for CHF-related
hospitalisations.
3.3. Pattern of all-cause unplanned hospitalisation
(1994 to 2005)
Over the 11 year period of follow-up, this cohort accu-
mulated 9342 unplanned admissions to hospital for any
cause, totalling 90,058 bed-days. Seasonal variation in the
pattern of these admissions was observed (see Table 4). July
was consistently observed to have the highest rate of all-
cause unplanned hospitalisations with the exception being
males aged ≥75 years, for whom the highest rate of ad-
missions was observed in August. The lowest hospitalisation
rates were recorded in either December or February.
3.4. Pattern of all-cause mortality (1994 to 2005)
Over the same period of follow-up, 2010 patients (68%)
died. Seasonal variation in mortality was observed: a
significantly higher crude mortality rate was recorded
when adjusted for the number of patients at risk in August
Fig. 1. CHF-related hospitalisation rate according to month of the year. Graph depicts mean high and low temperatures for the month [10,11].
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relative to February: 23 (95% CI: 20 to 27) vs. 12 (95%
CI: 10 to 15) deaths per 1000 patients at risk respectively,
pb0.001 (see Table 5). Fig. 2 depicts seasonal trends in all-
cause mortality according to age and sex. The risk of a
patient dying in the cooler winter months was double that of
dying in the hot summer months (RR 2.0, 95% CI 1.7 to 2.5).
The calculated average annual mortality rate for the
general South Australian population for this period (1994
to 2005) was 8 deaths per 1000 at risk, for those aged
≥75 years it was 73 deaths per 1000 at risk (or 6 deaths per
month per 1000 at risk). The annual mortality rate for males
and females was 8 vs. 7 deaths per 1000 at risk respectively.
Table 5
Seasonal variations in the rate of all-cause mortality
Total
events
Average monthly
event rate a
High vs. low months b Observed vs.
expected rate c
/1000 at risk (95% CI) /1000 at risk (95% CI) p value
All (n=2961) 2010 19 August: 23 (20 to 27) 0.040
(16 to 22) February: 12 (10 to 15) b0.001
Female (n=1471) 1009 19 September: 24 (20 to 29) NS (0.078)
(15 to23) February: 12 (9 to 15) 0.004
Male (n=1490) 1001 19 July: 26 (22 to 31) 0.019
(15 to 23) February: 13 (9 to 16) 0.021
Agedb75 years (n=1262) 707 12 July: 17 (14 to 21) 0.039
(9 to 16) February: 7 (5 to 10) 0.013
Aged≥75 years (n=1699) 1303 27 August: 34 (29 to 41) 0.045
(22 to 32) February: 18 (14 to 23) 0.005
Female agedb75 years (n=469) 244 10 September: 14 (10 to 20) NS (0.241)
(7 to 16) February: 6 (3 to 10) NS (0.069)
Female aged≥75 years (n=1002) 765 26 September: 32 (26 to 40) NS (0.175)
(20 to 33) February: 16 (12 to 22) 0.018
Male agedb75 years (n=793) 463 13 July: 20 (16 to 26) 0.038
(10 to 18) March: 8 (5 to 12) 0.030
Male aged≥75 years (n=697) 538 29 August: 39 (31 to 50) NS (0.091)
(22 to 38) February: 20 (15 to 29) NS (0.135)
a Averagemonthly event rate was calculated by dividing the average accumulated number of patients at risk per month by the average accumulated events per month.
b p≤0.005 for all comparisons of low vs. high monthly rates.
c Difference between the calculated average monthly event rate and the observed (for high or low months) monthly event rate.
Table 4
Seasonal variations in the rate of all-cause hospitalisations
Total
events
Average monthly
event rate a
High vs. low months b Observed vs.
expected rate c
/1000 at risk (95% CI) /1000 at risk (95% CI) p value
All (n=2961) 9342 87 July: 113 (107 to 120) b0.001
(82 to 93) February: 73 (68 to 79) 0.001
Female (n=1471) 4583 86 July: 116 (107 to 126) b0.001
(78 to 94) December: 66 (59 to 74) b0.001
Male (n=1490) 4759 89 July: 111 (102 to 120) 0.001
(81 to 98) February: 70 (63 to 78) 0.001
Agedb75 years
(n=1262)
3560 61 July: 78 (70 to 86) 0.001
(55 to 61) December: 50 (45 to 57) 0.021
Aged≥75 years
(n=1699)
5782 119 July: 156 (145 to 168) b0.001
(109 to 129) February: 97 (88 to 106) 0.001
Female agedb75 years
(n=469)
1326 56 July: 72 (61 to 84) 0.041
(47 to 67) December: 43 (35 to 53) 0.047
Female aged≥75 years
(n=1002)
3257 109 July: 151 (137 to 166) b0.001
(97 to 122) December: 84 (74 to 96) 0.003
Male agedb75 years
(n=793)
2234 64 July: 82 (72 to 92) 0.012
(56 to 74) February: 54 (46 to 63) NS (0.084)
Male aged≥75 years
(n=697)
2525 134 August: 164 (147 to 184) 0.015
(118 to 152) February: 99 (85 to 115) 0.002
a Averagemonthly event rate was calculated by dividing the average accumulated number of patients at risk per month by the average accumulated events per month.
b p≤0.001 for all comparisons of low vs. high monthly rates.
c Difference between the calculated average monthly event rate and the observed (for high or low months) monthly event rate.
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For the patients in this cohort, the calculated average
annual crude mortality is 228 deaths per 1000 at risk per year
(19 deaths per 1000 at risk per month, see Table 5). In those
aged ≥75 years we would expect 324 deaths per year per
1000 at risk (27 deaths per month per 1000 at risk). There is a
remarkable difference between the expected monthly
mortality for South Australians compared with those
included in this cohort. The attributable risk (%) for CHF
for those aged ≥75 years included in this cohort is 77.8%.
4. Discussion
This represents one of the first studies to formally
identify the phenomenon of seasonal variations in CHF-
related morbidity and mortality in a predominantly Medi-
terranean-style climate comprising mild winters and warm
to hot summer months. A seminal report from France in-
corporated data from a similar climate but also included data
from milder northern regions of France, [4] whilst a more
comparable study in Spain involved a smaller patient po-
pulation [2]. Consistent with these and other reports from
the northern hemisphere [1,3] we identified a significant
winter peak and summer trough in CHF-related events and
all-cause mortality and morbidity in patients with CHF.
Specifically, we made two key observations: 1) that CHF
patients living in South Australia experience the same
seasonal differences in CHF-related morbidity and all-cause
mortality as observed in northern hemisphere CHF patient
populations, and 2) that these CHF patients appear to be able
to tolerate appreciably hot temperatures in the summer
months (temperature range 8.0 °C to 44.3 °C) [10,11], a
period which was associated with the lowest event rates in
this CHF patient cohort.
Boulay et al. [4] reported a 20% peak above average in
CHF-related mortality in January and 15% below average
for August [4]. CHF-related hospitalisations followed a
similar trend [4]. The typical winter and summer tempera-
tures that these patients were exposed to were colder than the
typical winter and summer temperatures to which partici-
pants in this current cohort were exposed. For example, the
mean daily maximum temperature for Paris in January over
the period 1971 to 2000 was 6.9 °C and in August, 24.6 °C
[16]. A Spanish study reported that CHF-related hospitali-
sation rate peaked in January (25% above average) and was
one third less than the average in August [2]. These Spanish
CHF patients may have been exposed to a slightly warmer
climate, with mean daily maximum of 9.7 °C in January and
mean daily maximum of 30.7 °C in August [16]. In this
South Australian-based study, we found that the CHF-
related hospitalisation rate peaked in the equivalent winter
month of July (40% above the expected monthly rate) and
was just over one third less in the summer month of
February. The mean daily summer temperature to which
these CHF patients residing in South Australia were exposed
was a minimum of 15.5 °C to a maximum of 29.3 °C (1997–
2007 summer temperatures ranged from 8.0 °C to 44.3 °C),
in winter the mean daily minimum temperature was 7.4 °C to
16.7 °C (1997–2007 winter temperatures ranged from
−0.4 °C to 30.4 °C) [10,11].
One prior southern hemisphere study of seasonal variation
in events in CHF patients from Argentina found that CHF-
related hospitalisations and in-hospital deaths peaked in July
(mean maximum daily temperature 21 °C) and were lowest in
April (mean daily temperature 13 °C) [5,17].
Studies of seasonal variations in morbidity and mortality
in CHF patient populations living in notably cooler northern
hemisphere climates (Scotland and Quebec) have also
reported similar winter peaks and summer troughs [1,3].
Relative to these South Australian findings and despite con-
siderable differences between the two climates, Stewart et al.
[1] reported similar seasonal variations in event rates in the
Scottish population. CHF hospitalisations, concurrent respira-
tory disease and all-causemortality across thewhole population
exhibited seasonal variation [1]. Consistent with the current
Fig. 2. All-cause mortality rate according to sex and months of the year. Graphs depict mean high and low temperatures for the month [10,11].
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report, greatest variation in CHF-related hospitalisation rate
and all-cause mortality (i.e. those most vulnerable to climatic
variations) was observed in those aged ≥75 years. The tem-
peratures to which the Scottish population was exposed are
dramatically cooler than those to which our South Australian
CHF patients were exposed. In January, the mean (1971–2000)
maximum daily temperature in Scotlandwas 6.2 °C and in July,
the mean maximum daily temperature was 18.8 °C [16].
To date, published Australian reports of seasonality in
cardiovascular events have been limited to coronary artery
disease [18–21]. The most recent study reported seasonal
variation in coronary artery deaths, with a peak observed in
July similar to our findings for all-cause mortality and
hospitalisations with the lowest event rate observed in summer
months [20].
When considering similar patterns of seasonal variations
across several different patient populations and climates, our
data supports the hypothesis that it is the “relative” difference
in temperature driving the seasonal variation, rather than an
“absolute” temperature difference. Even though the tempera-
ture experienced by these South Australian CHF patients in
summer is much higher and the winter temperature consider-
ably warmer than that experienced by northern hemisphere
populations, the same summer trough and winter peak in event
rates are observed. It seems that event rates peak when
temperatures fall to their lowest point and the lowest rates are
observed when temperatures are at the warmest. It could,
therefore, be hypothesised that there is no “ideal” temperature
range for CHF patients, more that there is an ideal temperature
range for each patient population. A pertinent review on cli-
mate change and human health [22] highlights that populations
typically display an optimum temperature and that mortality
rates rise at temperatures which occur outside this comfort
zone.
The current results show evidence of acclimatisation in
these patients.Whilst themajority were born inAustralia, 47%
were immigrants to Australia, mainly from Europe. Over a
period of 30 or more years up to a lifetime these patients have
adapted to the South Australian climate and even the physical
vulnerability afforded by CHF has not exposed them to
increased risk of events in hot summer months. The forecast
increase in average world temperature (1.4–5.8 °C) by 2100
[22] raises concerns about the impact of heat on fragile patient
populations. There are several published reports of increased
mortality in heat waves [23] some of which examine the
impact on vulnerable populations such as patients with car-
diovascular disease [24] or CHF [25].
We have seen from these data that greater seasonal variation
was observed in CHF-hospitalisation rates relative to all-cause
hospitalisation rates. There may be a number of reasons for this
observed difference. During the winter period we have seen that
the proportion of concurrent respiratory illness is much higher
than at other periods. Therefore, it is more likely that an
admission to hospital for a patientwithCHFwith pneumonia for
example, would be coded with CHF and respiratory disease
discharge codes, thusmakingCHF-related admission ratesmore
sensitive to specific seasonalmorbidity. Furthermore,we limited
our identification of CHF-related admissions to the first or
second discharge code, and hence admissions with a CHF-
related discharge code beyond the second position would be
counted as all-cause admission so the seasonal variation
observed in all-cause hospitalisations may not be due to non-
CHF-related morbidity, but may represent instances of CHF-
related hospitalisation with a CHF-related discharge code in the
third or greater position. Theremay also be healthcareworkforce
issues and lifestyle factors which may account for low
admission rates seen in summer months.
What are the potential mechanisms underlying the
apparent paradox of reduced CHF-related morbidity and
mortality in the hot Australian summer given that empirical
and anecdotal evidence suggests that heat tolerance may be
impaired in patients with cardiovascular disease and in
particular, in patients with CHF?
Two recent studies offer further clarification into the phy-
siological effects of heat stress on thermoregulatory responses
in CHF patients [26,27]. Cui et al. found that cutaneous vaso-
dilator responses to heating were significantly reduced in
patients with CHF, whereas sweating responses were not
impaired [26]. In a small Australian study, CHF patients
exhibited impaired thermoregulatory responses to heat
exposure, possibly facilitated by lower skin blood flow [27].
The seasonal trends observed in this current cohort raise the
question of whether impaired thermoregulation can increase
the risk of morbidity and mortality in these patients. Both
studies [26,27] exposed patients to temperatures of up to 38 °C
for periods of up to 90 min. It is not unheard of for Adelaide,
the capital of SouthAustralia, to experience several continuous
days of temperatures above 35 °C with little relief overnight,
these “heat waves” tend to occur in January and February.
Whilst some tolerance to these high temperatures may be
explained by air conditioning, it is unlikely that all 2961
patients lived in air conditioned accommodation; in fact, these
results seem to suggest that theremay be some benefit of hotter
weather for those with CHF. Though limited, there is some
research in favour of the use of heat for patients with CHFwith
suggestions that thermal hydrotherapy [28] or saunas [29]may
improve quality of life and CHF symptoms.
An increase in event rates in colder winter months has
been postulated to be due to increased haemodynamic stress
and neurohormonal activation [30] which may lead to myo-
cardial ischaemia and precipitation of cardiac arrhythmias
[31] and acute heart failure [32]. The incidence of respiratory
infections increases in colder months and the contribution of
this concurrent illness on already fragile patients with CHF
cannot be underestimated.
There are several clinical implications of these findings.
Along with previous reports, these findings provide evidence
for increasing the intensity of CHF-management strategies
prior to periods with expected higher event rates. The im-
portance of pneumococcal and influenza vaccination in this
patient population is highlighted. Our results further em-
phasise the burden of CHF born by the hospital system
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during the winter months and warrant consideration of the
potential cost-savings of alternative strategies to reduce this
financial and resource burden. Such strategies must be aimed
at reducing the vulnerability of these patients to cold weather
and concurrent respiratory infection. Further research into
the physiological mechanisms behind thermoregulation in
CHF patients needs to be conducted as the temperature
mortality/morbidity relationship most likely varies between
climatic zones and patient populations.
There are a number of limitations that require comment.
Firstly, unlike other reports, these data are based on a cohort
of patients from a single tertiary institution. We do however
have more detailed clinical data than similar reports
published previously. Whilst this cohort was established to
examine morbidity and mortality in these patients, it was not
prospectively established to examine the current hypothesis;
therefore we do not have data relating to factors which may
influence susceptibility to cold and heat such as body mass
index, smoking status, type of residence, heating or cooling
of patients' homes and socioeconomic status. Moreover, we
did not consider our findings in relation to air pollution data,
barometric pressure or humidity. CHF-related hospitalisa-
tions were identified using ICD discharge coding, and though
shown to be useful and accurate in identifying hospitalisa-
tions related to CHF, discharge codes have been shown to
underestimate hospital events related to CHF in a UK
population [33]. Therefore, it is likely that we may have
missed some CHF-related events in this cohort or that these
may have been classified as all-cause admissions. We had
limited access to echocardiogram reports for these patients,
thus we were reliant on diagnosis of CHF confirmed by
angiography or clinical diagnosis determined by a cardiol-
ogist according to the Framingham criteria. Consistent with
other reports, we had limited data to differentiate between
patients with predominantly systolic heart failure compared
to those with preserved systolic function.
5. Summary
Despite these limitations we have demonstrated clear sea-
sonal variations in CHF-related morbidity and mortality in a
cohort of patients living in South Australia, and therefore,
exposed to relatively mild winters and warm to hot summers.
These data suggest that relative (rather than absolute) changes
in temperature and climatic conditions drive this global phe-
nomenon. Attention needs to be paid to the impact of hot
weather on patients with CHF; however, these data suggest
that warmer temperatures may not be as detrimental for pa-
tients with CHF as previously thought.
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